Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Menu

    Trastuzumab Emtansine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ENHERTU Shows iDFS Benefit in High-Risk Early Breast Cancer
    ENHERTU Shows iDFS Benefit in High-Risk Early Breast Cancer

    29 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250928521193/en/ENHERTU-Demonstrated-Highly-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Invasive-Disease-Free-Survival-Versus-T-DM1-in-DESTINY-Breast05-Phase-3-Trial-in-Patients-with-High-Risk-Early-Breast-Cancer-Following-Neoadjuvant-Therapy

    BUSINESSWIRE
    29 Sep 2025
    Share Share
    Kadcyla Is the First Targeted Therapy to Show OS Benefit in Breast Cancer
    Kadcyla Is the First Targeted Therapy to Show OS Benefit in Breast Cancer

    09 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231208002957/en/Genentech%E2%80%99s-Kadcyla-Is-the-First-Targeted-Therapy-to-Show-Significant-Overall-Survival-Benefit-in-People-With-HER2-Positive-Early-Stage-Breast-Cancer-With-Residual-Invasive-Disease-After-Neoadjuvant-Treatment

    BUSINESSWIRE
    09 Dec 2023
    Share Share
    Seagen says Tukysa combo hits main goal in Phase III breast cancer study
    Seagen says Tukysa combo hits main goal in Phase III breast cancer study

    17 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230816497169/en

    BUSINESSWIRE
    17 Aug 2023
    Share Share
    ENHERTU Achieved Overall Survival, Reducing the Risk of Death by 36%
    ENHERTU Achieved Overall Survival, Reducing the Risk of Death by 36%

    07 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221207005239/en

    BUSINESSWIRE
    07 Dec 2022
    Share Share
    Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial
    Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial

    07 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221207005734/en

    BUSINESSWIRE
    07 Dec 2022
    Share Share
    Genentech's Biologic Kadcyla (Trastuzumab Emtansine) Receives Approval in U.S.
    Genentech's Biologic Kadcyla (Trastuzumab Emtansine) Receives Approval in U.S.

    02 Feb 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427

    FDA
    02 Feb 2022
    Share Share